ClinicalTrials.gg
TerminatedNCT01875003Updated Jun 30, 2026Results posted

A Study of Lebrikizumab in Adolescent Participants With Uncontrolled Asthma Who Are on Inhaled Corticosteroids and a Second Controller Medication

A Phase 3 interventional study of Lebrikizumab and Placebo in Asthma, sponsored by Hoffmann-La Roche. Terminated at 81 sites in 21 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-06-30.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing lebrikizumab in Asthma — none open to participants now, none under way, none of them phase 3. lebrikizumab · Asthma.

Enrollment
3rd of 12
346 · median 224
Started
2013
with 2 others
Phase 3
5 of 12
none open now
Registered
8th of 12
by date
Lead sponsor
7 of 12
Hoffmann-La Roche

Among the 12 studies testing lebrikizumab in Asthma, this one is the 3rd largest by enrollment, is one of 3 that started in 2013, is one of 5 in phase 3, and was the 8th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 12 studies testing lebrikizumab in Asthma is open now. The open studies under Asthma, anywhere →

About lebrikizumab

lebrikizumab: first FDA approval 2024 (EBGLYSS), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing lebrikizumab in Asthma as a file.
02

Study summary

This randomized, multicenter, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy, safety, and tolerability of lebrikizumab in adolescent participants with asthma whose disease remains uncontrolled despite daily treatment with inhaled corticosteroids (ICS) therapy and at least one second controller medication. Participants will be randomized in a 1:1:1 ratio to receive double-blind treatment with either lebrikizumab ('High' or 'Low') or placebo, administered as subcutaneous (SC) every 4 weeks (Q4W) for 52 weeks, in addition to their standard-of-care therapy. This will be followed by an optional 52-week double-blind active-treatment extension. The anticipated time on study treatment is up to 104 weeks. Participants who complete the study to Week 104, discontinue prematurely or decide not to take part in the optional active-treatment extension will transition to the 20-week safety follow-up period.

03

Conditions studied

  • Asthma

Browse trials for

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Asthma diagnosis for greater than or equal to (>/=) 12 months prior to Visit 1
  • Bronchodilator response during screening
  • Pre-bronchodilator of 40 percent (%) - 90% predicted at both Visits 2 and 3
  • On high dose ICS therapy for >/= 6 months prior to Visit 1
  • On an eligible second controller medication for 6 months prior to Visit 1
  • Uncontrolled asthma as defined by the protocol both during screening and at the time of randomization
  • Demonstrated adherence with controller medication during the screening period

Exclusion criteria

Exclusion Criteria:

  • History of severe allergic reaction or anaphylactic reaction to a biologic agent or known to any component of the lebrikizumab injection
  • Maintenance oral therapy within 3 months prior to Visit 1
  • Treatment with systemic (oral, intravenous [IV], or intramuscular [IM]) corticosteroids within 4 weeks prior to Visit 1 or during the screening period
  • Treatment with intra-articular corticosteroids within 4 weeks prior to Visit 1 or during the screening period or anticipated need for intra-articular corticosteroids during the course of the study
  • Infection that meets the following criteria: Any infection requiring hospital admission or requiring treatment with IV or IM antibiotics within 4 weeks prior to Visit 1 or during screening; any active infection that required treatment with oral antibiotics within 2 weeks prior to Visit 1 or during screening; upper or lower respiratory tract infection within 4 weeks prior to Visit 1 or during screening; active parasitic infection or Listeria monocytogenes infection within 6 months prior to Visit 1 or during screening
  • History of active tuberculosis requiring treatment
  • Known immunodeficiency, including, but not limited to, (HIV) infection
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • History of cystic fibrosis, bronchiectasis, and/or other lung disease other than asthma
  • Diagnosis or history of or current evaluation for potential malignancy
  • Current smoker or former smoker with a history of greater than (>) 10 pack-years
  • History of alcohol or drug abuse
  • Past and/or current use of any anti- interleukin (IL) -13 or anti-IL-4/IL-13 therapy, including lebrikizumab
  • Use of other monoclonal antibody therapy, including omalizumab, within 6 months or 5 drug half-lives (whichever is longer) prior to Visit 1
  • Initiation of or change in allergen immunotherapy within 3 months prior to Visit 1 or during screening
  • History of bronchial thermoplasty
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
346 participants (actual)

Study arms

  • Experimental
    Lebrikizumab High

    Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 micrograms \[mcg\] of fluticasone propionate dry powder inhaler \[DPI\] or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (high dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.

    Drug: Lebrikizumab · Drug: Standard of Care

  • Experimental
    Lebrikizumab Low

    Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab (low dose) Q4W for 52 weeks during placebo-controlled period and up to 76 weeks or 104 weeks for participants who will be willing to take part in optional active-treatment extension period.

    Drug: Lebrikizumab · Drug: Standard of Care

  • Placebo comparator
    Placebo

    Participants with uncontrolled asthma on ICS therapy (total daily dose of 500-2000 mcg of fluticasone propionate DPI or equivalent) and a second controller medication, will receive SC injection of lebrikizumab matching placebo Q4W for 52 weeks during placebo-controlled period and then SC injection of lebrikizumab at high or low dose will be administered from Weeks 52 to 76 or 104 to participants who are willing to take part in optional active-treatment extension period.

    Drug: Lebrikizumab · Drug: Placebo · Drug: Standard of Care

Interventions

  • Lebrikizumab will be administered as SC injection at high or low dose Q4W.

  • DrugPlacebo

    Lebrikizumab matching placebo will be administered as SC injection Q4W.

  • DrugStandard of Care

    Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists \[LABAs\], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.

06

What researchers measure

Primary outcomes

  1. Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period

    An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.

    Time frame: Baseline up to Week 52

Secondary outcomes

  1. Percent Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52

    FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. The percentage change in pre-bronchodilator FEV1 was defined as the change in FEV1 (in liters) from baseline divided by the FEV1 (in liters) at baseline multiplied by 100.

    Time frame: Week 52

  2. Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52

    FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.

    Time frame: Week 52

  3. Time to First Asthma Exacerbation

    An asthma exacerbation was defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids was defined as treatment with oral, IV, or IM corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Median time to first protocol-defined asthma exacerbation was estimated using Kaplan-Meier analysis. 95% Confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

    Time frame: Baseline up to Week 52

  4. Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 52

    Measurement of FeNO (in parts per billion \[ppb\]) was performed using a hand-held portable NIOX MINO® device, in accordance with guidelines published by the American Thoracic Society (ATS) and described in the pulmonary function testing manual.

    Time frame: Week 52

  5. Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Overall Score at Week 52

    The Standardized AQLQ+12 was used to assess the participants' asthma-specific health-related quality of life. The AQLQ+12 had a recall specification of 2 weeks. The AQLQ+12 was a 32-item questionnaire with 4 domains: activity limitations, symptoms, emotional function, and environmental stimuli. Each of the 32 questions were scored on a scale 1-7. The overall AQLQ+12 score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7 indicated no impairments due to asthma, and a score of 1 indicated severe impairment.

    Time frame: Week 52

  6. Change From Baseline in Asthma Rescue Medication Use at Week 52

    Participants were allowed to use short-acting bronchodilators as asthma rescue medication. Baseline asthma rescue medication use was defined as the average number of puffs per day over the 7 days prior to and on the day of randomization. Participants must have recorded their asthma rescue medication use for at least 4 days to have a baseline score calculated. The post-baseline asthma medication use for any timepoint was defined as the average number of puffs per day over the last 28 days on or prior to the timepoint. Participants must have recorded their asthma rescue medication use for at least 14 days during a 28-day interval to have a score calculated for the respective timepoint. For nebulizer use, one treatment (inhalation) was considered equivalent to 4 puffs.

    Time frame: Week 52

  7. Rate of Urgent Asthma-Related Health Care Utilization (HCU) Events

    Urgent asthma-related HCU events included hospitalizations, emergency department visits, and acute care visits. Rate of urgent asthma-related HCU events = total number of urgent asthma-related HCU events divided by total follow-up time in patient years.

    Time frame: Baseline up to Week 52

  8. Injection Acceptability Questionnaire (IAQ) Score

    The acceptability of the injections of study drug was addressed by measuring the level of pain that participants experienced. Participants assessed pain associated with study drug administration using the IAQ within 10 minutes of study drug administration. The IAQ score ranged from 0 to 10; where 0 = no pain and 10 = worst pain imaginable.

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48

  9. Minimum Observed Serum Concentration (Ctrough) for Lebrikizumab

    Participants who received at least one dose of lebrikizumab and had at least one post-baseline evaluable sample were included in the analysis. Results of post-dose samples which were less than reportable were set to 0.045 micrograms per milliliter (mcg/mL) that is half of minimum quantifiable concentration value (0.09 mcg/mL).

    Time frame: Predose (Hour 0) at Weeks 4, 12, 24, 36, and 52

07

Results

Posted Jun 30, 2026
Limitations and caveats
The enrollment was closed, and dosing was terminated in this study following the sponsor's decision to discontinue development of lebrikizumab. Thus, this study was treated as exploratory (rather than confirmatory).

Participant flow

Participant flow — Overall Study
MilestonePlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgPlacebo/Lebrikizumab 37.5 mgPlacebo/Lebrikizumab 125 mg
Started561131163031
Completed030311614
Not completed5683851417
Withdrew: Study terminated by sponsor356166913
Withdrew: Withdrawal by subject1613541
Withdrew: Lost to follow-up40100
Withdrew: Adverse event12200
Withdrew: Physician decision02100
Withdrew: Missing04912
Withdrew: Other01100
Withdrew: Pregnancy00001

Outcome measures

PrimaryRate of Asthma Exacerbations During 52-Week Placebo Controlled Period

An asthma exacerbation is defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids is defined as treatment with oral, intravenous (IV), or intramuscular (IM) corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Rate of asthma exacerbation = total number of exacerbation events divided by total follow-up time in patient years.

Time frame:
Baseline up to Week 52
Reported as:
Number · events per patient year
Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period
events per patient yearPlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Rate of Asthma Exacerbations During 52-Week Placebo Controlled Period0.430.260.21
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Adjusted rate ratio: 0.60 · 95% CI 0.35 to 1.03
  • Placebo vs Lebrikizumab 125 mg · Adjusted rate ratio: 0.49 · 95% CI 0.28 to 0.83
SecondaryPercent Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52

FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. The percentage change in pre-bronchodilator FEV1 was defined as the change in FEV1 (in liters) from baseline divided by the FEV1 (in liters) at baseline multiplied by 100.

Time frame:
Week 52
Reported as:
Mean · percent change
Percent Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 52
percent changePlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Percent Change From Baseline in Pre-Bronchodilator Forced Expiratory Volume in 1 Second (FEV1) at Week 5219 ± 325 ± 320 ± 3
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Difference in adjusted means: 6 · 95% CI -2 to 14
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: 1 · 95% CI -7 to 9
SecondaryAbsolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52

FEV1 is the maximal volume of air exhaled in the first second of a forced expiration from a position of full inspiration. The baseline FEV1 was obtained from the last spirometric analysis performed before the first study treatment administration. Reported is the absolute change from baseline in FEV1 to the end of the placebo-controlled period at Week 52.

Time frame:
Week 52
Reported as:
Mean · millilitre (mL)
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52
millilitre (mL)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Absolute Change From Baseline in Pre-Bronchodilator FEV1 at Week 52370 ± 54568 ± 53423 ± 54
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Difference in adjusted means: 198 · 95% CI 53 to 342
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: 53 · 95% CI -92 to 198
SecondaryTime to First Asthma Exacerbation

An asthma exacerbation was defined as new or increased asthma symptoms (including wheeze, cough, dyspnea, chest tightness, and/or night-time awakening due to these symptoms) that lead to treatment with systemic corticosteroids or to hospitalization. Treatment with systemic corticosteroids was defined as treatment with oral, IV, or IM corticosteroids for at least 3 days or an emergency department visit with at least 1 dose of IV or IM corticosteroids. Median time to first protocol-defined asthma exacerbation was estimated using Kaplan-Meier analysis. 95% Confidence interval (CI) for median was computed using the method of Brookmeyer and Crowley.

Time frame:
Baseline up to Week 52
Reported as:
Median · weeks
Time to First Asthma Exacerbation
weeksPlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Time to First Asthma ExacerbationNA (NA to NA)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Hazard ratio (hr): 0.40 · 95% CI 0.22 to 0.73
  • Placebo vs Lebrikizumab 125 mg · Hazard ratio (hr): 0.37 · 95% CI 0.21 to 0.66
SecondaryChange From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 52

Measurement of FeNO (in parts per billion \[ppb\]) was performed using a hand-held portable NIOX MINO® device, in accordance with guidelines published by the American Thoracic Society (ATS) and described in the pulmonary function testing manual.

Time frame:
Week 52
Reported as:
Mean · ppb
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 52
ppbPlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Change From Baseline in Fractional Exhaled Nitric Oxide (FeNO) at Week 523.93 ± 2.81-18.05 ± 2.70-26.40 ± 2.76
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Difference in adjusted means: -21.97 · 95% CI -29.39 to -14.55
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: -30.33 · 95% CI -37.87 to -22.78
SecondaryChange From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Overall Score at Week 52

The Standardized AQLQ+12 was used to assess the participants' asthma-specific health-related quality of life. The AQLQ+12 had a recall specification of 2 weeks. The AQLQ+12 was a 32-item questionnaire with 4 domains: activity limitations, symptoms, emotional function, and environmental stimuli. Each of the 32 questions were scored on a scale 1-7. The overall AQLQ+12 score is the mean of the responses to each of the 32 questions, and ranges from 1 to 7. A score 7 indicated no impairments due to asthma, and a score of 1 indicated severe impairment.

Time frame:
Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Overall Score at Week 52
units on a scalePlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Change From Baseline in Standardized Asthma Quality of Life Questionnaire for 12 Years and Older (AQLQ+12) Overall Score at Week 521.05 ± 0.111.17 ± 0.111.21 ± 0.11
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Difference in adjusted means: 0.12 · 95% CI -0.18 to 0.41
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: 0.15 · 95% CI -0.14 to 0.44
SecondaryChange From Baseline in Asthma Rescue Medication Use at Week 52

Participants were allowed to use short-acting bronchodilators as asthma rescue medication. Baseline asthma rescue medication use was defined as the average number of puffs per day over the 7 days prior to and on the day of randomization. Participants must have recorded their asthma rescue medication use for at least 4 days to have a baseline score calculated. The post-baseline asthma medication use for any timepoint was defined as the average number of puffs per day over the last 28 days on or prior to the timepoint. Participants must have recorded their asthma rescue medication use for at least 14 days during a 28-day interval to have a score calculated for the respective timepoint. For nebulizer use, one treatment (inhalation) was considered equivalent to 4 puffs.

Time frame:
Week 52
Reported as:
Mean · puffs per day
Change From Baseline in Asthma Rescue Medication Use at Week 52
puffs per dayPlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Change From Baseline in Asthma Rescue Medication Use at Week 52-0.64 ± 0.24-0.68 ± 0.24-0.50 ± 0.23
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Difference in adjusted means: -0.04 · 95% CI -0.67 to 0.58
  • Placebo vs Lebrikizumab 125 mg · Difference in adjusted means: 0.14 · 95% CI -0.48 to 0.77
SecondaryRate of Urgent Asthma-Related Health Care Utilization (HCU) Events

Urgent asthma-related HCU events included hospitalizations, emergency department visits, and acute care visits. Rate of urgent asthma-related HCU events = total number of urgent asthma-related HCU events divided by total follow-up time in patient years.

Time frame:
Baseline up to Week 52
Reported as:
Number · events per patient year
Rate of Urgent Asthma-Related Health Care Utilization (HCU) Events
events per patient yearPlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Rate of Urgent Asthma-Related Health Care Utilization (HCU) Events0.210.080.06
Statistical analysis
  • Placebo vs Lebrikizumab 37.5 mg · Ratio of adjusted hcu rate: 0.40 · 95% CI 0.16 to 1.00
  • Placebo vs Lebrikizumab 125 mg · Ratio of adjusted hcu rate: 0.27 · 95% CI 0.10 to 0.72
SecondaryInjection Acceptability Questionnaire (IAQ) Score

The acceptability of the injections of study drug was addressed by measuring the level of pain that participants experienced. Participants assessed pain associated with study drug administration using the IAQ within 10 minutes of study drug administration. The IAQ score ranged from 0 to 10; where 0 = no pain and 10 = worst pain imaginable.

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48
Reported as:
Mean · units on a scale
Injection Acceptability Questionnaire (IAQ) Score
units on a scalePlaceboLebrikizumab 37.5 mgLebrikizumab 125 mg
Baseline (n= 107, 100, 105)3.5 ± 2.63.5 ± 2.33.9 ± 2.6
Week 4 (n= 101, 102, 105)3.7 ± 2.74.1 ± 2.63.9 ± 2.7
Week 8 (n= 91, 95, 102)3.7 ± 2.53.7 ± 2.43.5 ± 2.4
Week 12 (n= 92, 92, 96)3.4 ± 2.43.4 ± 2.73.5 ± 2.5
Week 16 (n= 87, 88, 95)3.2 ± 2.53.2 ± 2.63.3 ± 2.5
Week 20 (n= 84, 84, 87)3.1 ± 2.43.0 ± 2.63.1 ± 2.4
Week 24 (n= 80, 82, 85)3.3 ± 2.33.1 ± 2.53.3 ± 2.1
Week 28 (n= 82, 81, 84)2.9 ± 2.22.8 ± 2.42.8 ± 2.2
Week 32 (n= 83, 79, 80)2.9 ± 2.22.9 ± 2.73.0 ± 2.1
Week 36 (n= 77, 73, 80)3.1 ± 2.33.1 ± 2.73.1 ± 2.1
Week 40 (n= 70, 69, 74)3.0 ± 2.33.0 ± 2.42.7 ± 2.1
Week 44 (n= 58, 65, 73)2.9 ± 2.12.9 ± 2.23.2 ± 2.4
Week 48 (n= 58, 60, 67)2.9 ± 2.32.9 ± 2.62.7 ± 2.2
SecondaryMinimum Observed Serum Concentration (Ctrough) for Lebrikizumab

Participants who received at least one dose of lebrikizumab and had at least one post-baseline evaluable sample were included in the analysis. Results of post-dose samples which were less than reportable were set to 0.045 micrograms per milliliter (mcg/mL) that is half of minimum quantifiable concentration value (0.09 mcg/mL).

Time frame:
Predose (Hour 0) at Weeks 4, 12, 24, 36, and 52
Reported as:
Mean · mcg/mL
Minimum Observed Serum Concentration (Ctrough) for Lebrikizumab
mcg/mLLebrikizumab 37.5 mgLebrikizumab 125 mg
Week 4 (n= 47, 50)3.25 ± 1.5812.2 ± 5.28
Week 12 (n=42, 40)5.72 ± 2.8121.7 ± 9.37
Week 24 (n= 28, 29)7.15 ± 6.2325.7 ± 9.84
Week 36 (n= 18, 23)3.88 ± 2.9223.9 ± 9.87
Week 52 (n= 4, 0)NA ± NA—

Adverse events

Collected over Baseline up to 24 weeks after last dose of study treatment (overall 124 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/56 (0%)3/56 (5.4%)23/56 (41.1%)
Lebrikizumab 37.5 mg0/113 (0%)6/113 (5.3%)67/113 (59.3%)
Lebrikizumab 125 mg0/116 (0%)8/116 (6.9%)72/116 (62.1%)
Placebo/ Lebrikizumab 37.5 mg0/30 (0%)3/30 (10%)23/30 (76.7%)
Placebo/ Lebrikizumab 125 mg0/31 (0%)4/31 (12.9%)24/31 (77.4%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgPlacebo/ Lebrikizumab 37.5 mgPlacebo/ Lebrikizumab 125 mg
AsthmaRespiratory, thoracic and mediastinal disorders1/562/1132/1161/302/31
SinusitisInfections and infestations0/560/1130/1161/300/31
Type 1 diabetes mellitusMetabolism and nutrition disorders0/560/1130/1161/300/31
HeadacheNervous system disorders0/560/1130/1161/300/31
Abdominal painGastrointestinal disorders0/560/1130/1160/301/31
Abortion spontaneousPregnancy, puerperium and perinatal conditions0/560/1130/1160/301/31
DiarrhoeaGastrointestinal disorders1/560/1130/1160/300/31
VomitingGastrointestinal disorders1/560/1130/1160/300/31
DehydrationMetabolism and nutrition disorders1/560/1131/1160/300/31
DyspnoeaRespiratory, thoracic and mediastinal disorders1/560/1130/1160/300/31
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgPlacebo/ Lebrikizumab 37.5 mgPlacebo/ Lebrikizumab 125 mg
AsthmaRespiratory, thoracic and mediastinal disorders12/5625/11331/11611/3015/31
PharyngitisInfections and infestations5/5610/11318/1168/304/31
NasopharyngitisInfections and infestations4/5614/11313/1166/307/31
HeadacheNervous system disorders2/568/11311/1163/306/31
Upper respiratory tract infectionInfections and infestations3/5616/11311/1162/302/31
BronchitisInfections and infestations2/5610/1136/1164/304/31
GastroenteritisInfections and infestations1/563/1133/1163/301/31
RhinitisInfections and infestations1/565/1136/1163/303/31
Acute sinusitisInfections and infestations0/562/1133/1161/303/31
TonsillitisInfections and infestations2/569/1138/1162/303/31

Baseline characteristics

The intent-to-treat (ITT) population included all randomized participants who received at least one dose of study medication or have any post-baseline efficacy data.

Age, Continuous
Age, Continuous(years)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgTotal
Mean14.1 ± 1.714.2 ± 1.514.2 ± 1.614.2 ± 1.6
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgTotal
Female494359151
Male687057195
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgTotal
Hispanic or Latino394233114
Not Hispanic or Latino777181229
Unknown or Not Reported1023
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgTotal
American Indian or Alaska Native3115
Asian3339
Native Hawaiian or Other Pacific Islander0000
Black or African American9131335
White847574233
More than one race0112
Unknown or Not Reported18202462
Age group (years)
Age group (years)(Participants)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgTotal
12 to 14716467202
15 to 17464949144
Baseline Use of Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA)
Baseline Use of Inhaled Corticosteroid (ICS) and Long-Acting Beta-Agonist (LABA)(Participants)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgTotal
ICS < 1000 µg/day or no LABA878888263
ICS >= 1000 µg/day and LABA30252883
Number of Asthma Exacerbations in Last 12 Months
Number of Asthma Exacerbations in Last 12 Months(Asthma Exacerbations)PlaceboLebrikizumab 37.5 mgLebrikizumab 125 mgTotal
Mean1.6 ± 2.11.4 ± 1.91.7 ± 1.91.6 ± 1.9
08

Study locations

81 sites
  • Southern California Research Center
    Mission Viejo, California 92691, United States
  • Bensch Research Associates
    Stockton, California 95207, United States
  • Colorado Children's Hospital; The Breathing Institute
    Aurora, Colorado 80045, United States
  • IMMUNOe Research Centers
    Centennial, Colorado 80112, United States
  • Asthma & Allergy; Associates, P.C.
    Colorado Springs, Colorado 80907, United States
  • Abel and Buchheim
    Miami, Florida 33165, United States
  • Sarasota Clinical Research
    Sarasota, Florida 34239, United States
  • Georgia Pain Clinic
    Marietta, Georgia, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Asthma, Allergy & Sinus Center
    Baltimore, Maryland 21236, United States
  • Urban Health Plan, Inc.
    The Bronx, New York 10459, United States
  • TTS Research
    Boerne, Texas 78006, United States
  • Allergy & Asthma Res Ctr PA
    San Antonio, Texas 78251, United States
  • South Texas Allergy and Asthma Medical Professionals
    San Antonio, Texas 78251, United States
  • Bridgerland Clinical Research
    North Logan, Utah 84341, United States
  • O & O Alpan, LLC
    Fairfax, Virginia 22030, United States
  • INAER
    Buenos Aires, C1425BEN, Argentina
  • Instituto Respirar
    Mendoza, M5500GFA, Argentina
  • Centro Integral de Medicina Respiratoria (CIMER)
    San Miguel de Tucumán, T4000CHE, Argentina
  • Investigaciones en Patologias Respiratorias
    San Miguel de Tucumán, T4000IAR, Argentina
  • Instituto Del Buen Aire
    Santa Fe, S3000ASF, Argentina
  • CEMER Centro Médico de Enfermedades Respiratorias
    Vicente López, B1602DQD, Argentina
  • Centro de Referencia em Enfermidades Respiratorias e Alergia - CEAR
    Salvador, Estado de Bahia 41940-455, Brazil
  • Santa Casa de Misericordia de Porto Alegre
    Porto Alegre, Rio Grande do Sul 90020-090, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, Rio Grande do Sul 90610-000, Brazil
  • Faculdade de Medicina do ABC - FMABC
    Santo André, São Paulo 09060-650, Brazil
  • Pesquisare Saúde Sociedade Simples
    Santo André, São Paulo 09080-000, Brazil
  • Instituto de Pesquisa Clínica e Medicina Avançada Ltda
    São Paulo, São Paulo 05437-010, Brazil
  • CMPC/Clinica de Alergia Martti Antila
    Sorocaba, São Paulo 18040-425, Brazil
  • Private Practice - Dr. Brian D. Lyttle
    London, Ontario N6A 5B8, Canada
  • Hospital Santa Clara
    Bogotá, Colombia
  • Hofstetr Alois MUDr. s.r.o.
    Jihlava, 586 01, Czechia
  • Alergologie Teplice, s.r.o.
    Teplice, 415 01, Czechia
  • Hopital Charles Nicolle; cic
    Rouen, 76031, France
  • Universitaetsklinikum Frankfurt
    Frankfurt, 60528, Germany
  • Evangelisches Krankenhaus Hamm
    Hamm, 59063, Germany
  • Semmelweis Egyetem; Belgyogyaszati es Hematologiai Klinika
    Budapest, 1088, Hungary
  • Heim Pál Gyermekkórház
    Budapest, 1089, Hungary
  • Kenezy Korhaz Rendelointezet
    Debrecen, 4031, Hungary
  • Szegedi Tudomanyegyetem Szent-Gyorgyi Albert Klinikai Kozpont
    Szeged, 6720, Hungary
  • Papp és Társa Bt.
    Szigetvár, 7900, Hungary
  • Rambam Health Care Campus
    Haifa, 3109600, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Schneider Children's Medical Center
    Petah Tikva, 49100, Israel
  • Chaim Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Fondazione IRCCS Policlinico San Matteo
    Pavia, Lombardy 27100, Italy
  • Centro de Investigacion Medico Biologico y Terapia Avanzada, S.C.
    Guadalajara, Jalisco 44130, Mexico
  • Instituto Jalisciense de Investigacion Clinica S.A. de C.V.
    Santa Cecilia, Jalisco 44700, Mexico
  • Grupo Medico Camino
    DF, Mexico CITY (federal District), Mexico
  • Unidad de Investigacion Clinica En Medicina (Udicem) S.C.
    Monterrey, Nuevo León 64718, Mexico
  • Consultorio Especialidad Alergologia Pediatrica
    Villahermosa, 86035, Mexico
  • Clinica Internacional
    Lima, Lima 1, Peru
  • Centro de Investigación Ricardo Palma
    Lima, LIMA 27, Peru
  • Malopolskie Centrum Alergologii
    Krakow, 30-727, Poland
  • SPZOZ Uniwersytecki Szpital Kliniczny nr 1 im. Norberta Barlickiego Uniwersytetu Medycznego w Lodzi
    Lodz, 90-153, Poland
  • Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii im. M. Kopernika w Lodzi
    Lodz, 93-513, Poland
  • Centrum Alergologii Teresa Hofman
    Poznan, 60-214, Poland
  • ALERGO-MED Specjalistyczna Przychodnia Lekarska Sp. z o. o
    Tarnów, 33-100, Poland
  • Klinika Chorób Wewnetrznych i Alergologii MSW
    Warsaw, 02-507, Poland
  • Hospital Infante D. Pedro; Servico de Imunoalergologia
    Aveiro, 3814-501, Portugal
  • Hospital Particular do Algarve - Unidade de Faro
    Faro, 8005-226, Portugal
  • Hospital CUF Porto; Servico de Imunoalergologia
    Senhora Da Hora - Porto, 4460-188, Portugal
  • Imunoalergologia Dzurilla s.r.o.
    Nitra, 949 01, Slovakia
  • Uni of Cape Town Lung Inst.
    Cape Town, 7925, South Africa
  • Sebastian Peter
    Durban, 4001, South Africa
  • WWCT Lakeview Hospital
    Johannesburg, 1501, South Africa
  • Bothe ke Bontle Health Services
    Pretoria, 0101, South Africa
  • Soweto Clinical Trial Centre
    Soweto, 1818, South Africa
  • Hospital Universitario Germans Trias i Pujol; Servicio de Farmacia
    Badalona, Barcelona 08916, Spain
  • Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
    Sabadell, Barcelona 8208, Spain
  • Hospital de Manises
    Manises, Valencia 46940, Spain
  • National Cheng Kung Univ Hosp
    Tainan, 00704, Taiwan
  • Municipal Medical Institution; Chernivtsi Regional Children's Hospital
    Chernivtsi, 58023, Ukraine
  • Public Institution City Clinical Hospital # 6 of Dnipropetrovsk Regional Board
    Dnipro, 49000, Ukraine
  • State Institution of Pediatrics Obstetrics and Gynecology of NAMSU
    Kiev, 04050, Ukraine
  • Municipal Institution "Kryvyi Rih City Clinical Hospital #8" of Dnipropetrovsk Regional Council
    Kryvyi Rih, 50082, Ukraine
  • SI National Institute of Phthisiology and Pulmonology n.a. F.G.Yanovskyi under NAMS of Ukraine
    Kyiv, 03680, Ukraine
  • SI Research Centre of Radiation Medicine of AMSU
    Kyiv, 3115, Ukraine
  • Municipal Institution Zaporizhzhya Regional Clinical Child Hospital
    Zaporizhzhya, 69063, Ukraine
  • Birmingham Heartlands Hospital
    Birmingham, B9 5SS, United Kingdom
  • University of Leicester
    Leicester, LE1 7RH, United Kingdom
09

References and documents

Publications

  • Szefler SJ, Roberts G, Rubin AS, Zielen S, Kuna P, Alpan O, Anzures-Cabrera J, Chen Q, Holweg CTJ, Kaminski J, Putnam WS, Matthews JG, Kamath N. Efficacy, safety, and tolerability of lebrikizumab in adolescent patients with uncontrolled asthma (ACOUSTICS). Clin Transl Allergy. 2022 Jul 14;12(7):e12176. doi: 10.1002/clt2.12176. eCollection 2022 Jul. PubMed 35846226 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2013 to primary completion in Dec 2016, 40 months.

Results were first posted in Jun 2026, 9 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 7, 2013
First posted
Jun 11, 2013
StartActual
Aug 13, 2013
Primary completionActual
Dec 28, 2016
CompletionActual
Dec 28, 2016
Results first posted
Jun 30, 2026
Last update
Jun 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01875003
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 11, 2013
Start date
Aug 13, 2013
Primary completion
Dec 28, 2016
Completion
Dec 28, 2016
Results posted
Jun 30, 2026
Last update
Jun 30, 2026

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lebrikizumab

Start the discussion